Hemoglobin And Hematocrit Rise In End-Stage Renal Disease (ESRD) With PDpoetin: Results Of A Phase Ш, Multicenter Clinical Trial

Authors

  • Abbas Kebryaeezadeh Dept. of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • Effat Razeghi Dept. of Nephrology, Tehran University of Medical Sciences, Tehran, Iran
  • Mahboob Lesanpezeshki Dept. of Nephrology, Tehran University of Medical Sciences, Tehran, Iran
  • Mohammad-Reza Khatami Dept. of Nephrology, Tehran University of Medical Sciences, Tehran, Iran
  • Mohsen Naiebpoor Dept. of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • Reza Afshar Dept. of Nephrology, School of Medicine, Shahed University, Tehran, Iran.
  • Suzan Sanavi Dept. of Nephrology, School of Medicine, Shahed University, Tehran, Iran.
Abstract:

  Background and Objective: The anemia of ESRD is a complex disorder, associated with serious complications, which increases patients’ mortality and morbidity. Treatment of this anemia with recombinant human erythropoietin (rh-EPO) is well established. This clinical trial study was conducted within 20 months, from May 2005 to December 2006, in order to evaluate the efficacy of PDpoetin (rh-EPO alpha manufactured in Iran) in anemia correction of hemodialysis patients. Materials and Methods: The study population was composed of 80 patients, aged 22-84 years (with a mean of 49.5 ± 17.5 years), who were 60% male and 40% female. Data were collected by using a questionnaire and a consent form is signed by each patient. All data analysis was carried out using SPSS software and statistical t-test. We administered 80-120 U/kg (up to 300 U/kg in resistant cases) of PDpoetin, 3 times per week, subcutaneously. Then, we followed patients by weekly blood sampling for Hct and Hgb measurement. Results: PDpoetin raised Hct>1% and Hgb>0.3 g/dl per week in 81% and 79% of patients with CRPConclusion: PDpoetin may be an appropriate substitute for imported rh-EPOs. Further research studies are recommended.  

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

hemoglobin and hematocrit rise in end-stage renal disease (esrd) with pdpoetin: results of a phase ш, multicenter clinical trial

background and objective: the anemia of esrd is a complex disorder, associated with serious complications, which increases patients’ mortality and morbidity. treatment of this anemia with recombinant human erythropoietin (rh-epo) is well established. this clinical trial study was conducted within 20 months, from may 2005 to december 2006, in order to evaluate the efficacy of pdpoetin (rh-epo al...

full text

Safety and Efficacy of PDpoetin for Management of Anemia in Patients with end Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial

Recombinant human erythropoietin (rHuEPO) is available for correcting anemia. PDpoetin, a new brand of rHuEPO, has been certified by Food and Drug Department of Ministry of Health and Medical Education of Iran for clinical use in patients with chronic kidney disease. We conducted this post-marketing survey to further evaluate the safety and efficacy of PDpoetin for management of anemia in patie...

full text

ETIOLOGY OF END STAGE RENAL DISEASE (ESRD) IN SHIRAZ PEDIATRIC HEMODIALYSIS CENTER

One-hundred and sixteen children with ESRD were registered in Shiraz Pediatric Hemodialysis Center in Nemazee Hospital, a referral center in the south of Iran, from 1990 to 1999. Very small children are not dialysed in this center due to technical problems. The age range of children in this center was 2-16 years, mean age was 10.4±3.6 years and male to female ratio was 1.4. Major causes of ...

full text

Pericardial effusion in End Stage Renal Disease (ESRD): Report of 8 cases and review of the literature

Backgrounds: Pericardial effusion, once common among dialysis patients, has become a rare entity in recent years. Due to its low incidence, its recognition has gained importance among internists, cardiologists, and nephrologists. It can be seen in pre-dialysis patients and in dialysis patients who are on hemodialysis or peritoneal dialysis. Methods: A retrospective study was performed. The sub...

full text

Burden of end-stage renal disease (ESRD) in Latin America.

INTRODUCTION End-stage renal disease (ESRD) represents a major challenge for Latin America (LA). Epidemiological information needed to assist in the development of ESRD care in the region. The Latin American Dialysis and Renal Transplant Registry (RLADTR), has published several reports and its continuity has implied a sustained effort of the entire LA Nephrology community. This paper summarizes...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 3  issue 3

pages  157- 160

publication date 2008-06-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023